News Sentiment

VYNE sentiment intelligence

Vyne Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.64 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-6.2% over one week, -1.7% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

VYNE Therapeutics Inc. (VYNE) reports 13.8% stake by Zhang Xiaofan

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction -6.2% Price reacting lower
Trend fit Trend active -1.7% over four weeks
Fair value -65.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 41
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
TradingView 8
TradingKey 6
Market source 5
simplywall.st 3
AD HOC NEWS 2
GuruFocus 1
Moomoo 1

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 12
Deals and strategy 10
Capital return 4
Regulatory and legal 2
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
TradingKey Direct company coverage

Vyne Therapeutics Inc (VYNE) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Vyne Therapeutics Inc (VYNE), noting its current valuation score of 7.83, ranking it 199 out of 387 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.29 and states that relevant data for P/B, P/S,

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 18:41
Source
TradingKey
TradingKey Direct company coverage

Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Vyne Therapeutics Inc (VYNE), detailing its current price momentum score as 3.58, ranking it 358 out of 387 in its industry. It highlights that the stock is trading between resistance at $0.69 and support at $0.61, suggesting suitabil

Tone
Negative 40/100
Event
Market update
Published
22 Jun 2026 17:40
Source
TradingKey
AD HOC NEWS Direct company coverage

VYNE Therapeutics Stock - Sunday background on a micro-cap dermatology player

This article provides a background overview of VYNE Therapeutics, a Nasdaq-listed micro-cap biopharmaceutical company focused on inflammatory skin conditions. It delves into the company's pipeline, management, regulatory reporting, clinical development risks, financial position,

Tone
Neutral 50/100
Event
Regulatory and legal
Published
21 Jun 2026 18:11
Source
AD HOC NEWS
TradingKey Direct company coverage

Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Vyne Therapeutics Inc (VYNE), focusing on its business segments, regional revenue, and profit contribution. It highlights that as of the updated data on April 6, relevant revenue data by business and region have not been disclosed by

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 07:39
Source
TradingKey
TradingKey Direct company coverage

Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a detailed historical overview of Vyne Therapeutics Inc (VYNE) dividend payouts and stock split events. It highlights that Vyne Therapeutics has not distributed any dividends over the past five years but has undergone several stock merger splits, notably an 1

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 Jun 2026 04:39
Source
TradingKey
TradingKey Direct company coverage

Vyne Therapeutics Inc (VYNE) Financial Health: Profitability & Balance Sheet Analysis

Vyne Therapeutics Inc (VYNE) currently holds a financial score of 6.55, ranking 241st out of 388 in the Biotechnology & Medical Research industry. Despite robust financial status, the company exhibits low operating efficiency. Its latest quarterly revenue saw a 57.43% year-over-y

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 00:40
Source
TradingKey